Last reviewed · How we verify

Losartan and amlodipine and hydrochlorothiazide

Hotel Dieu de France Hospital · FDA-approved active Small molecule

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: angiotensin II receptor blockade, calcium channel inhibition, and thiazide diuresis.

This triple-combination antihypertensive reduces blood pressure by blocking angiotensin II receptors, relaxing vascular smooth muscle, and reducing sodium and fluid retention. Used for Hypertension (high blood pressure).

At a glance

Generic nameLosartan and amlodipine and hydrochlorothiazide
SponsorHotel Dieu de France Hospital
Drug classAntihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)
TargetAngiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Losartan blocks angiotensin II receptors to reduce vasoconstriction and aldosterone secretion. Amlodipine inhibits L-type calcium channels in vascular smooth muscle to promote vasodilation. Hydrochlorothiazide acts as a thiazide diuretic to reduce blood volume and sodium reabsorption. Together, these agents provide synergistic antihypertensive effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: